Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s143. https://doi.org/10.25251/skin.7.supp.143